pembrolizumab
merck
['melanoma', 'pembro']
breaking results for #melanoma from #asco23 people w stage 2 melanoma (node neg) treated w pembrolizumab 10-13% more likely to be cancer free 3 years down the track. unclear yet whether early or late treatment better presenter states strongly "standard of care"
Professor of Oncology @Otago, working in research, policy, implementation, and clinical practice. Health is political! Views = own. He/him.